Register Login

ICU MEDICAL, INC. (ICUI)

Director Jain Vivek 🟡 adjusted position in 62.4K shares (2 derivative) of ICU MEDICAL INC/DE (ICUI) at $132.00 ($7.9M) Transaction Date: Mar 07, 2026 | Filing ID: 000001

Full text
Register to leave comments
  • News bot March 9, 2026, 8:22 p.m.

    🔍 Jain Vivek (Director)

    Company: ICU MEDICAL INC/DE (ICUI)

    Report Date: 2026-03-07

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 2
    • Holdings reported: 1
    • Total shares acquired: 112,917
    • Total shares sold: 175,336
    • Total shares held: 152,339

    Detailed Transactions and Holdings:

    • Acquired 5,282 shares of Common Stock (Direct)
      Date: 2026-03-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 71,790.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 2,919 shares of Common Stock (Direct)
      Date: 2026-03-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 68,871.00 | transaction_form_type: 4
    • Acquired 107,635 shares of Common Stock (Direct)
      Date: 2026-03-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 176,506.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 59,500 shares of Common Stock at $132.0 per share (Direct)
      Date: 2026-03-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 117,006.00 | transaction_form_type: 4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-03-07 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 152,339.00
    • Sold 5,282 shares of Common Stock (Derivative)
      Date: 2026-03-07 | Code: M | Exercise: 2026-03-07 | equity_swap_involved: 0 | shares_owned_after: 10,566.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4, F5
    • Sold 107,635 shares of Performance Shares (Derivative)
      Date: 2026-03-08 | Code: M | Expires: 2026-03-08 | Exercise: 2026-03-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F7, F2

    Footnotes:

    • F1: These securities are Restricted Stock Units.
    • F2: Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein.
    • F3: There is neither a purchase price nor an exercise price for the Restricted Stock Units.
    • F4: One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.
    • F5: These are restricted stock units that fully vest 3 years from the grant date.
    • F6: These Securities are Performance-based Restricted Stock Units (PRSU).
    • F7: There is neither a purchase price nor an exercise price for the PRSUs.

Search

News categories